We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood-Based Platelet RNA Tests Detects Cancer

By LabMedica International staff writers
Posted on 01 Dec 2015
Cancer is primarily diagnosed by clinical presentation, radiology, biochemical tests, and pathological analysis of tumor tissue, increasingly supported by molecular diagnostic tests.

A ribonucleic acid (RNA) test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analyzing a sample equivalent to one tiny sample of blood. More...
Using this new method for blood-based RNA tests of blood platelets, scientists have been able to identify cancer with 96% accuracy.

An international team of scientists including those at Umea University (Sweden) studied blood samples from 283 individuals of which 228 people had some form of cancer and 55 showed no evidence of cancer. To minimize effects of long-term storage of platelets at room temperature and loss of platelet RNA quality and quantity, samples were processed within 48 hours after blood collection. By comparing the blood samples RNA profiles, team could identify the presence of cancer with an accuracy of 96% among patients. Among the 39 patients in the study in which an early detection of cancer had been made, 100% of the cases could be identified and classified.

Tumor tissues of patients were analyzed for the presence of genetic alterations by tissue DNA sequencing, including next-generation sequencing SnaPShot (Thermo Fisher; Waltham MA, USA) assessing 39 genes over 152 exons with an average sequencing coverage of greater than 500. Immunohistochemistry and fluorescent in situ hybridization (FISH) were also used. In follow-up tests using the same method, the investigators could identify the origin of tumors with a so far unsurpassed accuracy of 71% in patients with diagnosed cancer in the lung, breast, pancreas, brain, liver, colon and rectum. The samples could also be sorted in subdivisions depending on molecular differences in the cancer form, which can be of great use in the choice of treatment method.

Jonas A. Nilsson, PhD, a coauthor of the study said, “Being able to detect cancer at an early stage is vital. We have studied how a whole new blood-based method of biopsy can be used to detect cancer, which in the future renders an invasive cell tissue sample unnecessary in diagnosing lung cancer, for instance. In the study, nearly all forms of cancer were identified, which proves that blood-based biopsies have an immense potential to improve early detection of cancer.” The study was published on October 29, 2015, in the journal Cancer Cell.

Related Links:

Umea University 
Thermo Fisher



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Gold Member
Pipette Management Software
VIALINK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.